NCT07106281

Brief Summary

The aim of this study is to investigate the effect of cronic GSE intake in crosstraining may have a favorable impact on biochemical markers, recovery, and performance.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2025

Completed
16 days until next milestone

First Posted

Study publicly available on registry

August 6, 2025

Completed
26 days until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2026

Completed
Last Updated

August 6, 2025

Status Verified

July 1, 2025

Enrollment Period

4 months

First QC Date

July 21, 2025

Last Update Submit

July 29, 2025

Conditions

Keywords

grape seed extractmuscle damageconcurrent exercisenutritionrecovery

Outcome Measures

Primary Outcomes (2)

  • Performance

    Performance measured through the countermovement jump

    48 hours

  • Performance

    Deep squat test at 70% of repetition maximum

    60 minutes

Secondary Outcomes (11)

  • Attention

    60 minutes

  • Performance: Weight used in the crosstraining session

    60 minutes

  • Performance: Time performed in the crosstraining session

    60 minutes

  • Subjective fatigue throug the the RPE scale

    60 minutes

  • Gastrointestinal distress

    60 minutes

  • +6 more secondary outcomes

Study Arms (2)

Grape seed extract

EXPERIMENTAL

600 mg of Grape seed extract

Dietary Supplement: Grape Seed Extract

Placebo

PLACEBO COMPARATOR

Preparation of colorants, sweeteners, aromas, and acidulants

Dietary Supplement: Placebo

Interventions

Grape Seed ExtractDIETARY_SUPPLEMENT

600mg of Grape Seed Extract

Grape seed extract
PlaceboDIETARY_SUPPLEMENT

Placebo

Placebo

Eligibility Criteria

Age18 Years - 35 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age: 18-35 years.
  • Body mass index: 18.5-30 kg/m2.
  • Ability to understand the instructions, objectives, and study protocol.
  • Minimum of 3 years of experience in crosstraining, with at least 6 hours of weekly training over the past 3 months.
  • Resident on the island of Tenerife.

You may not qualify if:

  • History of a significant adverse cardiovascular event, renal insufficiency, cirrhosis, eating disorder, weight control surgical intervention, or type 2 diabetes mellitus.
  • Any chronic pathology in which the intake of nutritional supplements, especially use of antioxidant supplements during the 4 weeks prior to the start of the study.
  • Any condition that, in the investigator's judgment, would impair the ability to participate in the study or represent a personal risk to the participant.
  • Use of medications that may affect the study results.
  • Unstable body weight for 3 months prior to the start of the study (\> 4 kg loss or gain in weight).
  • Active tobacco abuse or illicit drug use, or history of treatment for alcohol abuse.
  • On a special diet or prescribed for other reasons (e.g., celiac disease).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad de la Laguna

Santa Cruz de Tenerife, Spain

Location

MeSH Terms

Interventions

Grape Seed Extract

Intervention Hierarchy (Ancestors)

Plant ExtractsPlant PreparationsBiological ProductsComplex MixturesPharmaceutical Preparations

Central Study Contacts

Lucas Jurado-Fasoli, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

July 21, 2025

First Posted

August 6, 2025

Study Start

September 1, 2025

Primary Completion

December 20, 2025

Study Completion

January 31, 2026

Last Updated

August 6, 2025

Record last verified: 2025-07

Locations